FDA Grants Taletrectinib Priority Review for Advanced ROS1+ NSCLC
“The FDA has granted priority review to a new drug application for taletrectinib, an investigational next-generation ROS1 TKI, for the treatment of patients with advanced ROS1-positive non–small cell lung cancer (NSCLC), according to a news release from the drug’s developer, Nuvation Bio.”
Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC
“Key Takeaways – Nivolumab plus ipilimumab with CCRT did not significantly improve PFS over CCRT followed by durvalumab in stage III NSCLC. Median PFS and OS were comparable across treatment arms, with no new safety signals observed.”
The Evidence Gap: Immunotherapy Timing in Early-Stage NSCLC?
“Do patients with early-stage non–small cell lung cancer (NSCLC) benefit from continuing immunotherapy beyond surgery? The short answer: Oncologists don’t know for sure.”
2 friends beat lung cancer, urge screening for the at-risk
“Even before their lung cancer surgeries at Novant Health Forsyth Medical Center in Winston-Salem, Garry Hoover and Gary Pippin had a lot in common.”
#HearHer campaign aims to increase awareness of lung cancer among women
“Key takeaways: The #HearHer campaign focuses on gender disparities in lung cancer diagnosis and clinical trial enrollment. Clinicians should take women’s concerns seriously and make use of imaging for early detection.”
FDA Approves New Drug for Advanced Lung Cancer
“Dec. 19, 2024 – The FDA has approved a new drug called ensartinib for adults with a type of lung cancer called ALK-positive non-small-cell lung cancer (NSCLC). Sold under the brand name Ensacove, this drug is now a first-choice treatment for people with this type of cancer. It is for patients whose cancer has either grown nearby or spread to other parts of the body and who haven’t been treated with an ALK-blocking drug before.”
After Lung Cancer Treatment, Radiation Pneumonitis Can Mimic Tumor Growth
“The treatment for lung cancer with the “Cyber Knife” (thoracic stereotactic body radiation therapy) went well, but six months later the patient notices something wrong with her breathing, and a new round of imaging shows a growing mass at the tumor site. Instead of cancer recurrence, close examination of the new imaging studies show that the mass is acute radiation pneumonitis, characterized by acutely inflamed tissue around the treatment site.”
Study reveals immune-modulatory mechanism of lurbinectedin in small-cell lung cancer
“Researchers at the Icahn School of Medicine at Mount Sinai have identified the mechanism of action of a treatment for small-cell lung cancer (SCLC), one of the most aggressive and difficult-to-treat cancers. Published this week in Cell Reports Medicine, the study reveals that the drug lurbinectedin, an approved second-line therapy for SCLC, activates the STING-IFN signaling pathway to enhance the immune response against tumors.”
Microplastics in the Air May Be Leading to Lung and Colon Cancers
“Tires and degrading garbage shed tiny pieces of plastic into the air, creating a form of air pollution that UC San Francisco researchers suspect may be causing respiratory and other illnesses. A review of some 3,000 studies implicates these particles in a variety of serious health problems. These include male and female infertility, colon cancer and poor lung function. The particles also may contribute to chronic pulmonary inflammation, which can increase the risk of lung cancer.”
